Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT04671615
What this trial is testing

Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

Who this might be right for
Metastatic Breast Cancer
Pfizer 559
Not applicableStudy completedNCT02625935
What this trial is testing

Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients

Who this might be right for
Breast Cancer
NanoString Technologies, Inc. 206
Testing effectiveness (Phase 2)WithdrawnNCT05234606
What this trial is testing

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Who this might be right for
Urothelial CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer+2 more
Silverback Therapeutics
Testing effectiveness (Phase 2)Study completedNCT00633464
What this trial is testing

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerMetastatic Breast Cancer
R-Pharm 79
Early research (Phase 1)Study completedNCT02338349
What this trial is testing

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Who this might be right for
Advanced ER+, HER2-Negative Breast Cancer
Stemline Therapeutics, Inc. 57
Early research (Phase 1)Active Not RecruitingNCT02453620
What this trial is testing

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Adenocarcinoma+2 more
National Cancer Institute (NCI) 57
Not applicableEnded earlyNCT04436120
What this trial is testing

Treatment Resistance Following Anti-cancer Therapies

Who this might be right for
Disease Progression
Pfizer 38
Early research (Phase 1)WithdrawnNCT01333423
What this trial is testing

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center
Post-approval studies (Phase 4)Ended earlyNCT05183828
What this trial is testing

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+2 more
University of Washington 62
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07466927
What this trial is testing

Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases

Who this might be right for
HER2-negative Breast Cancer
Fudan University 30
Testing effectiveness (Phase 2)Temporarily pausedNCT05656131
What this trial is testing

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
wang shusen 80
Testing effectiveness (Phase 2)Ended earlyNCT01329627
What this trial is testing

Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer

Who this might be right for
Locally Advanced HER2-negative Breast Cancer
Instituto do Cancer do Estado de São Paulo 12
Early research (Phase 1)UnknownNCT05692661
What this trial is testing

A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerHER2-positive Breast Cancer
Shanghai Proton and Heavy Ion Center 24
Large-scale testing (Phase 3)UnknownNCT02404051
What this trial is testing

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CancerHormone Receptor Positive Tumor+2 more
Consorzio Oncotech 745
Not applicableStudy completedNCT03841266
What this trial is testing

Recurrence Risk Evaluation by 21-gene Detection

Who this might be right for
Relationship and Consistency Analysis
Xijing Hospital 220
Early research (Phase 1)Ended earlyNCT01149356
What this trial is testing

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+4 more
National Cancer Institute (NCI) 15
Large-scale testing (Phase 3)UnknownNCT03927456
What this trial is testing

SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 357
Testing effectiveness (Phase 2)Ended earlyNCT00790894
What this trial is testing

Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)

Who this might be right for
Metastatic Breast Cancer
Hellenic Cooperative Oncology Group 64
Testing effectiveness (Phase 2)Study completedNCT02282345
What this trial is testing

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Who this might be right for
Breast AdenocarcinomaDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene Mutation+2 more
M.D. Anderson Cancer Center 36
Testing effectiveness (Phase 2)Ended earlyNCT01980277
What this trial is testing

Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer

Who this might be right for
Breast Cancer
Institut Paoli-Calmettes 68
Next Page